O GoConqr está de visual novo! Conte para nós o que você achou.

Registre-se grátis

Quiz

MD25 Controlling release in vivo

Mer Scott 13 perguntas

Fazer o quiz

Este quiz tem tipos de pergunta que abrem no player de sempre.

Perguntas do quiz (13)

  1. 1Temporal control could be important for drugs which:
    • Have a time-dependent [blank_start]mechanism of action[blank_end] eg some cytotoxic drugs, [blank_start]antibiotics[blank_end]
    • Are [blank_start]unstable[blank_end] (short half life)
    • Need continuous [blank_start]exposure[blank_end]
    • Need [blank_start]multiple[blank_end] short periods of exposure
    1. Amechanism of action
    2. Bantibiotics
    3. Cunstable
    4. Dexposure
    5. Emultiple
  2. 2Spatial control could be important for drugs which are:
    • Highly [blank_start]toxic[blank_end], and have a [blank_start]narrow[blank_end] therapeutic window
    • Readily [blank_start]metabolized or excreted[blank_end]
    • Have a [blank_start]concentration-dependent[blank_end] mechanism of action
    1. Atoxic
    2. Bnarrow
    3. Cmetabolized or excreted
    4. Dconcentration-dependent
  3. 3A time-dependent mechanism of action means that the amount of [blank_start]time spent[blank_end] above the [blank_start]therapeutic level[blank_end] is more important than the peak drug concentration. Examples are some classes of antibiotics, and [blank_start]cycle specific cytotoxic[blank_end] cancer drugs.
    A concentration-dependent mechanism of action means [blank_start]peak concentration[blank_end] reached is more important than time spent above therapeutic level. Examples are [blank_start]non-cycle specific[blank_end] cytotoxic drugs (chemotherapy) & [blank_start]concentration-dependent killing[blank_end] antibiotics. Also known as ‘[blank_start]log kill[blank_end]’ agents.
    1. Atime spent
    2. Btherapeutic level
    3. Ccycle specific cytotoxic
    4. Dpeak concentration
    5. Enon-cycle specific
    6. Fconcentration-dependent killing
    7. Glog kill
  4. 4As dose is increased, non-cycle specific cytotoxic drugs become more effective.
    1. AVerdadeiro
    2. BFalso
  5. 5As duration of drug exposure is increased, cycle specific cytotoxic drugs become more effective.
    1. AVerdadeiro
    2. BFalso
  6. 6We can achieve controlled release in vivo by using prodrugs, IDDS, nanomedicines and nanoformulations. We can use nano-scale materials for therapeutic benefit, to modify [blank_start]kinetics[blank_end] of release (temporal control) – [blank_start]sustained or pulsatile[blank_end], [blank_start]location[blank_end] of release (spatial control) – crossing [blank_start]barriers[blank_end] (eg BBB, cell membrane, nuclear membrane), or at tissue [blank_start]site[blank_end] (eg tumor). We can therefore increase [blank_start]therapy efficacy[blank_end] and decrease [blank_start]side effects[blank_end] (drug toxicity and antibiotic resistance).
    1. Akinetics
    2. Bsustained or pulsatile
    3. Clocation
    4. Dbarriers
    5. Esite
    6. Ftherapy efficacy
    7. Gside effects
  7. 7Why use Nanoparticles?
    • Increase [blank_start]solubility[blank_end]
    • [blank_start]Protect[blank_end] active(s)
    • [blank_start]Co-delivery[blank_end] of multiple drugs
    • To control [blank_start]time[blank_end] of release (temporal)
    • To control [blank_start]location[blank_end] of release (spatial)
    1. Asolubility
    2. BProtect
    3. CCo-delivery
    4. Dtime
    5. Elocation
  8. 8The [blank_start]immune[blank_end] system has evolved to recognise and take up nm – µm complexes. This is bad for [blank_start]drugs[blank_end], though good for [blank_start]vaccines[blank_end]. Commonly we use ‘[blank_start]stealth[blank_end]’ technologies, eg coating NPs with [blank_start]polyethylene glycol[blank_end]; known as PEGylation.
    1. Aimmune
    2. Bdrugs
    3. Cvaccines
    4. Dstealth
    5. Epolyethylene glycol
  9. 9Tumour blood vessels are [blank_start]leaky[blank_end] so we can give [blank_start]passive[blank_end] tumor specific delivery by making NPs too [blank_start]large[blank_end] to leak through healthy vessels, but which will [blank_start]diffuse[blank_end] into tumors. This does depend on [blank_start]pressure[blank_end] inside the tumor - it may get leakage back out of the tumor into the blood vessel.
    1. Aleaky
    2. Bpassive
    3. Clarge
    4. Ddiffuse
    5. Epressure
  10. 10The half life of Peg-Dox is 55 hours, compared to 10 min for Dox, so it does
    not need to be given by continuous infusion (CI).
    1. AVerdadeiro
    2. BFalso

Informações

Descrição
PHCY211 (Medicines) Quiz sobre MD25 Controlling release in vivo, criado por Mer Scott em 27-05-2018.
Idioma
English
Visualizações
12
Avaliação
Ainda sem avaliações
Avalie este quiz
Avalie este quiz

Fale Conosco

Sobre o que é sua mensagem?

O que você acha do novo visual?

Você gostou?